Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Charles, Van Sant"'
Autor:
Gurunadh R, Chichili, Ronald, Smulders, Vicki, Santos, Beth, Cywin, Laura, Kovanda, Charles, Van Sant, Frank, Malinoski, Shite, Sebastian, George, Siber, Richard, Malley
Publikováno v:
Vaccine. 40:4190-4198
Pneumococcal diseases remain prevalent despite available polysaccharide and conjugate vaccines. This phase 1/2 study evaluated safety/tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine (ASP3772) based on high-affinity complexin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff0e031898303fc05bd358fa8af4a6af
https://doi.org/10.1016/j.vaccine.2022.05.079
https://doi.org/10.1016/j.vaccine.2022.05.079
Autor:
Dimitri Semizarov, Rick Lesniewski, Guido Sauter, Stephen K. Tahir, Gang Wang, Mark G. Anderson, Charles Van Sant, Edward T. Olejniczak
Cancer is a highly heterogeneous disease in terms of the genetic profile and the response to therapeutics. An early identification of a genomic marker in drug discovery may help select patients that would respond to treatment in clinical trials. Here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2a93be6ecf2f02b04c78232a3c5db95
https://doi.org/10.1158/1541-7786.c.6542718.v1
https://doi.org/10.1158/1541-7786.c.6542718.v1
Autor:
Dimitri Semizarov, Rick Lesniewski, Guido Sauter, Stephen K. Tahir, Gang Wang, Mark G. Anderson, Charles Van Sant, Edward T. Olejniczak
Supplementary Table S3 from Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f070759111d30eeaa00eabf58e85394
https://doi.org/10.1158/1541-7786.22520652
https://doi.org/10.1158/1541-7786.22520652
Autor:
Dimitri Semizarov, Rick Lesniewski, Guido Sauter, Stephen K. Tahir, Gang Wang, Mark G. Anderson, Charles Van Sant, Edward T. Olejniczak
Supplementary Table S2 from Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1259183c97ab1bb567b1d745725fa319
https://doi.org/10.1158/1541-7786.22520655.v1
https://doi.org/10.1158/1541-7786.22520655.v1
Autor:
Sou Boutsaboualoy, Thomas Marbury, Xuegong Wang, Erin C. Zook, Anne Koester, Ruishan Wu, Larry R. Smith, Kathy Cho, Peter L. Bonate, Ronald Goldwater, Ming Ye, Charles Van Sant, Diane Rammelsberg
Publikováno v:
Clinical pharmacology in drug developmentReferences. 9(4)
Cytomegalovirus (CMV) infection causes significant morbidity and mortality in immunocompromised transplant patients. ASP0113, a first-in-class DNA vaccine containing plasmids encoding CMV phosphoprotein 65 and glycoprotein B (gB), was evaluated in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf52f7943bd73b135d42f2ca8b2bebfd
https://pubmed.ncbi.nlm.nih.gov/32202705
https://pubmed.ncbi.nlm.nih.gov/32202705
Autor:
Al B. Benson, John Bridgewater, Igor Kiss, Jihong Chen, Carolyn Sasse, Sandra Vossen, Andrew Krivoshik, Ferry A.L.M. Eskens, Howard A. Ball, Anne Keating, Charles Van Sant
Publikováno v:
Clinical Cancer Research, 22(20), 5058-5067. American Association for Cancer Research Inc.
Purpose: Tivozanib, a selective inhibitor of VEGFR-1, -2, and -3, plus mFOLFOX6 in an advanced gastrointestinal cancer phase Ib study had encouraging antineoplastic activity and a tolerable safety profile. This randomized, open-label, phase II trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95348a748c8bc3cf7c06f595f725f03
https://doi.org/10.1158/1078-0432.ccr-15-3117
https://doi.org/10.1158/1078-0432.ccr-15-3117
Publikováno v:
Journal of Virology. 72:1731-1736
The translation elongation factor 1δ (EF-1δ) consists of two forms, a hypophosphorylated form (apparent M r , 38,000) and a hyperphosphorylated form (apparent M r , 40,000). Earlier Y. Kawaguchi, R. Bruni, and B. Roizman (J. Virol. 71:1019–1024,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8fa6e6f828ffd6c1aac5135ab82ecd1
https://doi.org/10.1128/jvi.72.3.1731-1736.1998
https://doi.org/10.1128/jvi.72.3.1731-1736.1998
Publikováno v:
Proceedings of the National Academy of Sciences. 94:7891-7896
An earlier report showed that a disabled mutant lacking both copies of the major regulatory gene (α4) of herpes simplex virus 1 induced DNA degradation characteristic of apoptosis in infected cells, whereas the wild-type virus protected cells from a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d9d2a883bba725199c76fdd5aa68c7b
https://doi.org/10.1073/pnas.94.15.7891
https://doi.org/10.1073/pnas.94.15.7891
Publikováno v:
BMC Medical Genomics, Vol 3, Iss 1, p 23 (2010)
BMC Medical Genomics
BMC Medical Genomics
Background Cancer is a heterogeneous disease caused by genomic aberrations and characterized by significant variability in clinical outcomes and response to therapies. Several subtypes of common cancers have been identified based on alterations of in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33ab7931420096b8dee0f16e4c2aaa40
http://www.biomedcentral.com/1755-8794/3/23
http://www.biomedcentral.com/1755-8794/3/23
Autor:
Guido Sauter, Stephen K. Tahir, Rick Lesniewski, Edward T. Olejniczak, Gang Wang, Mark G. Anderson, Dimitri Semizarov, Charles Van Sant
Publikováno v:
Molecular cancer research : MCR. 5(4)
Cancer is a highly heterogeneous disease in terms of the genetic profile and the response to therapeutics. An early identification of a genomic marker in drug discovery may help select patients that would respond to treatment in clinical trials. Here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e623043d96c801437844da161698dc5
https://pubmed.ncbi.nlm.nih.gov/17426248
https://pubmed.ncbi.nlm.nih.gov/17426248